Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Marketable securities, current

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndMarketable securities, current (Million JPY)YoY (%)
Mar 31, 20251,118-69.18%
Mar 31, 20243,628-18.75%
Mar 31, 20234,465+123.24%
Mar 31, 20222,000+0.00%
Mar 31, 20212,000+233.33%
Mar 31, 2020600-62.50%
Mar 31, 20191,600-20.00%
Mar 31, 20182,000+0.01%
Mar 31, 20172,000-0.00%
Mar 31, 20162,000+0.00%
Mar 31, 20152,000

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)